Iran Press/ Iran News: In a meeting held on Monday, Saghar Barati stated: "The results of clinical studies on SpikoGen COVID vaccine indicate that the vaccine has produced a robust immune response in 87% of recipients."
"The vaccine has been proved to be safe with an acceptable degree of tolerability, according to the results of the second phase of clinical trials," she noted.
"As a booster dose, SpikoGen vaccine induced a re-immune response and an increase in the mean concentration of antibodies," she added.
She said the first phase of the tests on the SpikoGen vaccine had been carried out in Australia, and the second and third phases began simultaneously in Iran.
She went on to highlight that the vaccine did not show any severe or specific side effects in the second and third stages of its clinical trial and can be used as a booster shot.
"Iran has already granted emergency use authorization to PastoCoVac COVID vaccine, produced jointly by Iran's Pasteur Institute and Cuba's Finlay Institute," Barati reiterated.
SpikoGen is a recombinant protein-based COVID-19 vaccine developed by South Australian-based biotech company Vaxine, collaborating with the Iranian company CinnaGen.
The health official stated that the SpikoGen vaccine enjoys all European standards.
The project's lead researcher also pointed out that the vaccine has no age limits for people, either healthy or with any pre-existing diseases.
"The vaccine yet takes time to get WHO's approval, Payam Tabarsi highlighted.
Regarding the mass production of the vaccine, Khashayar Roshan-Zamir, the other scientific director of the project, said: "Meeting Iran's all-out needs, the vaccine will be mass-produced and sent to the neighboring or other countries."
Iran's Health Ministry announced on January 17, 2022, 60,350,685 people have received the first dose of the COVID vaccine, 53,195,312 have received the second dose, 12,855,978 have received the third dose, and the total number of vaccines- in different types- injected in the country reached 126,401,975 doses.
224
Read More:
SpikoGen vaccine provides more than 80% immunity: Researcher
5 million doses of COVID-19 vaccine purchased by RCS enters Iran
